Cannabis Stock Cresco Labs Plunges 24% YTD: Time to Sell or Hold?

Cresco Labs (CRLBF) reported a challenging Q1 2025, with revenues declining 10% year-over-year to $165.8 million and adjusted EBITDA margins contracting significantly to 22% from 28.8%. The U.S.-centric cannabis operator faces persistent domestic regulatory headwinds, including a projected Q2 revenue dip due to an Illinois system transition, and intensifying competition from peers diversifying internationally. CRLBF shares are down 24% year-to-date against an industry rise, reflecting a deteriorating outlook and a Zacks #4 (Sell) rating due to limited upside and elevated risk.

Analysis

Cresco Labs (CRLBF) is facing significant fundamental pressure, as evidenced by its Q1 2025 results which saw a 10% year-over-year revenue decline to $165.8 million. Profitability has eroded substantially, with the adjusted gross margin sliding 220 basis points to 49.3% and the adjusted EBITDA margin contracting sharply from 28.8% to 22%. The company's U.S.-only operational focus exposes it directly to a challenging domestic market characterized by fragmented state-level regulations and restrictive federal laws, a key differentiator from competitors like Aurora Cannabis, Canopy Growth, and Tilray Brands, who are diversifying internationally. The near-term outlook appears challenging, with management warning of a potential Q2 revenue dip due to an Illinois system transition and analysts widening loss estimates for 2026 and 2027. This negative trajectory is reflected in the stock's performance, which has declined 24% year-to-date, in stark contrast to the broader industry's 6% gain, and is underscored by a Zacks Rank #4 (Sell) rating.

Key Decisions for Investors

• Given the combination of declining revenue, significant margin compression, and negative forward-looking guidance, investors should exercise extreme caution, as the stock's risk profile is elevated.
• Consider that Cresco's lack of international diversification presents a structural disadvantage compared to peers, potentially limiting its growth in a saturated and fragmented U.S. market.
• Closely monitor the upcoming Q2 results for the severity of the expected revenue dip in Illinois, as persistent top-line weakness could jeopardize the company's ability to execute its expansion and refinancing strategy.
• The stock's 24% year-to-date underperformance against the industry suggests that a potential turnaround is contingent on a major U.S. regulatory shift, which remains an uncertain catalyst.